Madrigal Pharmaceuticals

Pharma

'No weakness' in Madrigal's Rezdiffra MASH launch, says CEO

With sales of $103M in Q4 and $180M in its first nine months on the market, Madrigal's MASH treatment Rezdiffra has all the earmarks of a blockbuster.

Kevin Dunleavy Feb 27, 2025 11:19am

Recapping Fierce Pharma's top stories of the year

Dec 23, 2024 3:00am

Amid a new MASH market, ‘tremendous change’ is on the horizon

Nov 5, 2024 10:02am

Novo Nordisk's semaglutide delivers in phase 3 MASH study

Nov 1, 2024 10:38am

Madrigal's MASH drug Rezdiffra 'blew away' expectations in Q3

Oct 31, 2024 3:24pm

Madrigal Pharmaceuticals Rezdiffra Way Forward campaign

Madrigal maps out 'Way Forward' for MASH patients with Rezdiffra

Sep 6, 2024 6:30am